Single-Center Study: Evaluating the Diagnostic Performance and Safety of Contrast-Enhanced Ultrasound (CEUS) in Pregnant Women to Assess Hepatic Lesions

2019 ◽  
Vol 41 (01) ◽  
pp. 29-35 ◽  
Author(s):  
Vincent Schwarze ◽  
Constantin Marschner ◽  
Giovanna Negrão de Figueiredo ◽  
Johannes Rübenthaler ◽  
Dirk-André Clevert
Keyword(s):  
Pregnant Women ◽  
Diagnostic Performance ◽  
Imaging Modality ◽  
Color Doppler ◽  
Hepatic Metastases ◽  
Published Data ◽  
Single Center ◽  
Single Center Study ◽  
Hepatic Lesions ◽  
Center Study

Abstract Background Ultrasound is an essential imaging tool for evaluating physiological and pathological fetal or maternal conditions during pregnancy. Published data is limited with respect to the application of CEUS during pregnancy. CEUS has already been safely applied for assessing uteroplacental blood flow, cesarean scar pregnancy and invasive placenta percreta. CT and MRI scans during pregnancy must be thoroughly evaluated due to harmful ionizing radiation and cerebral gadolinium deposition, respectively. Purpose The aim of the present retrospective single-center study is to assess the diagnostic performance and safety of CEUS during pregnancy to evaluate hepatic lesions of unknown entity. Methods 6 pregnant patients who underwent CEUS between 2005 and 2014 (mean age: 32 years; mean weeks of pregnancy: 28 weeks) were included in this study. The applied contrast agent was a second-generation blood-pool agent (SonoVue®, Bracco, Milan, Italy). CEUS examinations were performed and interpreted by a single radiologist with experience since 2000 (EFSUMB Level 3). Results CEUS was safely performed on all included pregnant women without the occurrence of adverse fetal or maternal events. In the context of the present study, CEUS helped to safely differentiate hepatic metastases, focal nodular hyperplasia, atypical hemangioma, hepatic arteriovenous malformation and cystic echinococcosis. In two patients CEUS determined immediate therapy. Conclusion Although not clinically approved in obstetrics so far, CEUS is a safe imaging modality which, in addition to B-mode and color Doppler ultrasonography, may be applied during pregnancy for further medical indications and to provide helpful information.

Single-center study: the diagnostic performance of contrast-enhanced ultrasound (CEUS) for assessing renal oncocytoma

2020 ◽  
Vol 54 (2) ◽  
pp. 135-140 ◽  
Author(s):  
Vincent Schwarze ◽  
Constantin Marschner ◽  
Giovanna Negrão de Figueiredo ◽  
Thomas Knösel ◽  
Johannes Rübenthaler ◽  
...  
Keyword(s):  
Diagnostic Performance ◽  
Renal Oncocytoma ◽  
Contrast Enhanced Ultrasound ◽  
Single Center ◽  
Contrast Enhanced ◽  
Single Center Study ◽  
Center Study

Low titers of measles antibodies in Japanese pregnant women: A single-center study

2012 ◽  
Vol 39 (2) ◽  
pp. 500-503 ◽  
Author(s):  
Eriko Kanda ◽  
Koushi Yamaguchi ◽  
Masachi Hanaoka ◽  
Hideo Matsui ◽  
Haruhiko Sago ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Single Center ◽  
Single Center Study ◽  
Measles Antibodies ◽  
Japanese Pregnant Women ◽  
Center Study

Diagnostic performance of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for the evaluation of hypermetabolic lymphadenopathy mediastinum lower, posterior, and middle, detected by PET-CT with 18F-FDG (PET) (APOGEE Study).

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 798-798
Author(s):  
Dominique Bechade ◽  
Carine A. Bellera ◽  
Coralie Cantarel ◽  
Isabelle Soubeyran ◽  
Marc Debled ◽  
...  
Keyword(s):  
Lymph Nodes ◽  
Diagnostic Performance ◽  
Therapeutic Strategy ◽  
Mediastinal Lymphadenopathy ◽  
Single Center ◽  
Diagnostic Certainty ◽  
Pet Ct ◽  
Single Center Study ◽  
18F Fdg ◽  
Center Study

798 Background: In the context of a new cancer or relapse, the high sensitivity (Se) (95-100%) of PET-CT with 18F-FDG can lead to the demonstration of hypermetabolic mediastinal adenopathies. Its lower specificity (Sp) (89%) can require histological examination. We report the results of a prospective, single-center study evaluating the diagnostic performance of EUS-FNA in this indication. Methods: Prospective single-center study featuring patients in whom PET had revealed hypermetabolic mediastinal lymphadenopathy requiring diagnostic certainty. All EUS-FNA were performed with a 19-gauge needle (EchoTip, Cook Endoscopy). Main objective: To evaluate the diagnostic performance in terms of Se and Sp of EUS-FNA in the characterization of hypermetabolic mediastinal adenopathies in PET in the context of a new cancer or relapse. Secondary objectives: To evaluate the negative predictive value (NPV) of the EUS-FNA and to evaluate the percentage of surgical diagnostic procedures avoided. The standard technique was a thoraco-abdominopelvic CT scan at 6 months and at 12 months. Results: 52 patients were eligible and evaluable for the primary endpoint. The most common primary cancers were mammary (17.3%) and bronchial (13.5%). The lymph nodes were analyzed as malignant in 44.2% of cases, benign in 50% of cases and atypical or suspicious in 3.8% of cases. The malignant lymph nodes were metastatic for breast cancer in 21.7% of cases, bronchial cancer in 17.4% of cases, colorectal cancer in 17.4% of cases and prostate cancer in 13% of cases. The Se of the EUS-FNA was 92% (95% CI 0.74-0.99) and the Sp 100%. NPV was 87% (95% CI: 0.59-0.98). A diagnostic surgical procedure was necessary in 2% of the cases. PET and EUS-FNA often allowed the modification of the therapeutic strategy. Conclusions: When a confirmed diagnosis is required, the diagnostic accuracy of the minimally invasive procedure of EUS-FNA, is sufficiently robust to avoid a surgical diagnosis technique. The combination of PET and EUS-FNA may alter the therapeutic strategy that would have been considered after PET alone. Clinical trial information: NCT01892501.

Sign in / Sign up

Export Citation Format

Share Document